Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.

Autor: Volkers, Adriaan1 (AUTHOR) a.g.volkers@amsterdamumc.nl, Straatmijer, Tessa1,2 (AUTHOR), Duijvestein, Marjolijn3 (AUTHOR), Sales, Amber1 (AUTHOR), Levran, Amit1 (AUTHOR), van Schaik, Fiona4 (AUTHOR), Maljaars, Jeroen2 (AUTHOR), Gecse, Krisztina1 (AUTHOR), Ponsioen, Cyriel1 (AUTHOR), Grootjans, Joep1 (AUTHOR), Hanzel, Jurij5 (AUTHOR), Tack, Greetje6 (AUTHOR), Jansen, Jeroen7 (AUTHOR), Hoentjen, Frank3,8 (AUTHOR), de Boer, Nanne9 (AUTHOR), van der Marel, Sander10 (AUTHOR), Dijkstra, Gerard11 (AUTHOR), Oldenburg, Bas4 (AUTHOR), Löwenberg, Mark1 (AUTHOR), van der Meulen, Andrea2 (AUTHOR)
Zdroj: Alimentary Pharmacology & Therapeutics. Sep2022, Vol. 56 Issue 6, p1044-1054. 11p. 4 Charts, 2 Graphs.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje